Please provide your email address to receive an email when new articles are posted on . More than 11,000 clinicians attended the American Society for Radiation Oncology Annual Meeting in September ...
SAN FRANCISCO, September 26, 2025--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will present four abstracts at the ...
WEST WARWICK, R.I.--(BUSINESS WIRE)--Astro-Med, Inc. (NASDAQ: ALOT), a leading manufacturer of data visualization technology for the specialty printing and test and measurement markets, today ...
Phase III trial presented at ASTRO in San Francisco finds five-treatment regimen poised to become new standard of care. SAN FRANCISCO, Sept. 29, 2025 /PRNewswire/ -- Men with intermediate-risk ...
Company remains on track to submit NDA to the U.S. FDA for avasopasem for radiotherapy-induced severe oral mucositis by end of 2022 MALVERN, Pa., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, ...
MALVERN, Pa., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, ...
Presented in collaboration with the National Cancer Centre Singapore, this study marks the first validation of the ArteraAI Prostate Test in an Asian prostate cancer population. The test was shown to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results